Welcome to our dedicated page for ORASURE TECHNOLOGIES SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ORASURE TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ORASURE TECHNOLOGIES's regulatory disclosures and financial reporting.
OraSure Technologies, Inc. held its 2026 annual stockholder meeting, where stockholders approved an amendment and restatement of the 2000 Stock Award Plan to add authorization for 5,000,000 additional shares of common stock for awards. Stockholders also approved an amendment to the Certificate of Incorporation to declassify the board of directors over three years beginning with the fiscal 2027 annual meeting, so directors standing for election then and thereafter will serve one-year terms.
All three Class II director nominees were elected, Grant Thornton LLP was ratified as independent auditor for 2026, and the advisory vote on executive compensation passed. As of the April 10, 2026 record date, there were 71,965,612 shares of common stock outstanding.
OraSure Technologies Inc. director Steven Kyle Boyd reported a series of open-market purchases of the company’s Common Stock. Over three days, he bought a total of 75,000 shares at prices between $2.98 and $3.02 per share. Following these transactions, he directly owned 113,462 shares.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 33,661 shares of common stock as an equity award. The shares were granted at no cash cost to him and are structured as restricted stock. They cliff vest on May 12, 2028, meaning the entire award vests at once on that date if he continues serving on the Board. Vesting stops immediately if he voluntarily leaves the Board before that date.
OraSure Technologies director John D. Bertrand submitted a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing is administrative in nature and, in the data provided, does not report any share purchases, sales, or option exercises.
OraSure Technologies director Lelio Marmora reported a routine share disposition related to taxes, not an open-market trade. On the vesting of restricted shares, 28,406 common shares were withheld at $3.02 per share to cover associated tax liabilities.
After this tax-withholding disposition, Marmora directly holds 102,354 shares of OraSure Technologies common stock. This type of transaction is compensation-related and does not represent a discretionary purchase or sale in the open market.
OraSure Technologies director Robert W. McMahon reported a tax-withholding disposition of 22,888 shares of Common Stock at $3.02 per share. These shares were withheld to cover taxes due on the vesting of restricted shares, and McMahon now directly holds 77,031 shares.
OraSure Technologies director Nancy J. Gagliano reported a tax-related share disposition. On the vesting of restricted shares, 21,305 shares of common stock were withheld at a price of $3.02 per share to cover associated tax liabilities. After this withholding, she directly holds 138,949 OraSure common shares.
OraSure Technologies reported first quarter 2026 net revenues of $27.9 million, down 7% from $29.9 million a year earlier, as COVID-19 and risk assessment testing revenue largely disappeared while core revenue declined slightly. GAAP gross margin improved to 42.3% from 41.1%, and non-GAAP gross margin rose to 43.4% from 41.7%, reflecting better mix and cost control.
The company posted a GAAP operating loss of $23.3 million and a GAAP net loss of $22.4 million, compared with losses of $17.8 million and $16.0 million in the prior-year quarter. Diluted GAAP loss per share was $0.32, with non-GAAP diluted loss per share of $0.24. Cash and cash equivalents were $177.0 million as of March 31, 2026 after using $5 million to repurchase about 1.8 million shares. For the second quarter of 2026, OraSure guides total revenues to $27–$30 million and expects non-GAAP gross margin similar to the first quarter.
OraSure Technologies, Inc. files its Annual Report on Form 10-K describing its diagnostics and sample-management businesses, product portfolio, regulatory status, manufacturing footprint and certain 2025 developments.
The report states an aggregate market value of common equity held by non-affiliates of $218,472,693 and 69,126,173 shares outstanding as of February 28, 2026. It discloses the November 2025 acquisition of BioMedomics, 2025 product and pipeline highlights including FDA 510(k) submissions for a CT/NG rapid molecular self-test and a Colli-Pee at-home urine device, ongoing EUA and CLIA statuses for InteliSwab products, BARDA funding for Ebola test development, and continued U.S. manufacturing capacity including a target of more than 100 million tests annually.